• D Baratti, S Kusamura, D Nonaka, G D Oliva, B Laterza, and M Deraco.
• Department of Surgery, National Cancer Institute, Milan, Italy.
• Ann. Surg. Oncol. 2007 Oct 1;14(10):2790-7.

BackgroundMulticystic peritoneal mesothelioma (MPM) and well-differentiated papillary peritoneal mesothelioma (WDPPM) are exceedingly uncommon lesions with uncertain malignant potential and no uniform treatment strategy. The aim of the current study was to review our experience with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in these clinical settings.MethodsFour women with MPM and eight with WDPPM underwent 13 procedures of cytoreduction and close-abdomen HIPEC with cis-platin and doxorubicin. Seven patients had recurrent disease after previous debulking (one operation in five patients, two in one, four in one). Potential clinicopathological prognostic factors were assessed.ResultsOptimal cytoreduction (residual tumor nodules ConclusionsMPM and WDPPM are borderline tumors capable of transformation into potentially lethal processes. Definitive tumor eradication by means of cytoreduction and HIPEC seems more effective than debulking surgery in preventing disease recurrence or transition to aggressive malignancies.

45 keywords...

hide…